Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression

  • Authors:
    • Lei Zhao
    • Bo Jiang
    • Dong Wang
    • Wei Liu
    • Huawu Zhang
    • Weisheng Liu
    • Zhen Qiu
  • View Affiliations

  • Published online on: March 15, 2016     https://doi.org/10.3892/etm.2016.3164
  • Pages: 2005-2010
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma is the most common type of malignant bone tumor found in adolescents and young adults. The aim of the present study was to determine whether triptolide, a diterpene epoxide extracted from the Tripterygium plant, was able effectively decrease the viability of osteosarcoma cells. The underlying molecular mechanisms are also investigated. The human osteosarcoma cell lines U‑2 OS and MG‑63 were used in this study. The U‑2 OS and MG‑63 cells were treated with 0, 5, 10, 25 or 50 nM triptolide. Cells treated with dimethyl sulfoxide only were used as the no drug treatment control. A commercial MTT kit was used to determine the effects of triptolide on cells. Mitogen‑activated protein kinase phosphatase‑1 (MKP‑1) is frequently overexpressed in tumor tissues, possibly related to the failure of a number of chemotherapeutics. Heat shock protein 70 (Hsp70) is a chaperone molecule that is able to increase drug resistance. The protein expression levels of MKP‑1 and Hsp70 were determined using western blot analysis. The results indicate that triptolide effectively reduced the viability of the osteosarcoma cells. Furthermore, triptolide was found to effectively reduce MKP‑1 expression and Hsp70 levels. Further analysis showed that triptolide reduced MKP‑1 mRNA expression in the U‑2 OS and MG‑63 cells. Triptolide reduced Hsp70 mRNA expression levels in U‑2 OS and MG‑63 cells. These results suggest that triptolide effectively decreases the viability of osteosarcoma cells. These effects may be associated with the decreased expression of MKP‑1 and Hsp70 levels. These results suggest that triptolide may be used in the treatments of osteosarcoma.
View Figures
View References

Related Articles

Journal Cover

May-2016
Volume 11 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao L, Jiang B, Wang D, Liu W, Zhang H, Liu W and Qiu Z: Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression. Exp Ther Med 11: 2005-2010, 2016
APA
Zhao, L., Jiang, B., Wang, D., Liu, W., Zhang, H., Liu, W., & Qiu, Z. (2016). Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression. Experimental and Therapeutic Medicine, 11, 2005-2010. https://doi.org/10.3892/etm.2016.3164
MLA
Zhao, L., Jiang, B., Wang, D., Liu, W., Zhang, H., Liu, W., Qiu, Z."Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression". Experimental and Therapeutic Medicine 11.5 (2016): 2005-2010.
Chicago
Zhao, L., Jiang, B., Wang, D., Liu, W., Zhang, H., Liu, W., Qiu, Z."Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression". Experimental and Therapeutic Medicine 11, no. 5 (2016): 2005-2010. https://doi.org/10.3892/etm.2016.3164